Cancer Predictive Genetic Testing Market Research Report – Segmentation by Test Type (Germline Testing, Somatic Testing); Cancer Type (Breast Cancer, Colorectal Cancer, Ovarian Cancer, Other Cancer Types); End-User (Hospitals and Clinics, Diagnostic Laboratories, Research Institutes); and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-15141
Format:
Region: Global
Chapter 1. CANCER PREDICTIVE GENETIC TESTING MARKET – Scope & Methodology
1.1. Market Segmentation
1.2. Assumptions
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. CANCER PREDICTIVE GENETIC TESTING MARKET – Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.3. COVID-19 Impact Analysis
2.3.1. Impact during 2023 – 2030
2.3.2. Impact on Supply – Demand
Chapter 3. CANCER PREDICTIVE GENETIC TESTING MARKET – Competition Scenario
3.1. Market Share Analysis
3.2. Product Benchmarking
3.3. Competitive Strategy & Development Scenario
3.4. Competitive Pricing Analysis
3.5. Supplier - Distributor Analysis
Chapter 4. CANCER PREDICTIVE GENETIC TESTING MARKET - Entry Scenario
4.1. Case Studies – Start-up/Thriving Companies
4.2. Regulatory Scenario - By Region
4.3 Customer Analysis
4.4. Porter's Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. CANCER PREDICTIVE GENETIC TESTING MARKET - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. CANCER PREDICTIVE GENETIC TESTING MARKET – by Test Type
6.1. Germline Testing
6.2. Somatic Testing
Chapter 7. CANCER PREDICTIVE GENETIC TESTING MARKET – By Cancer Type
7.1. Breast Cancer
7.2. Colorectal Cancer
7.3. Ovarian Cancer
7.4. Other Cancer Types
Chapter 8. CANCER PREDICTIVE GENETIC TESTING MARKET – By End-User
8.1 Hospitals and Clinics
8.2. Diagnostic Laboratories
8.3. Research Institutes
Chapter 9. CANCER PREDICTIVE GENETIC TESTING MARKET – By Region
9.1. North America
9.2. Europe
9.3.The Asia Pacific
9.4.Latin America
9.5. Middle-East and Africa
Chapter 10. CANCER PREDICTIVE GENETIC TESTING MARKET– Company Profiles – (Overview, Product Portfolio, Financials, Developments)
10.1. 23&Me Inc.
10.2. Abbott Laboratories
10.3. Myriad Genetics Inc.
10.4. Danaher Corporation
10.5. Illumina Inc.
10.6. DiaSorin Spa (Luminex Corporation)
10.7. BioRad Laboratories Inc.
10.8. PerkinElmer Inc.
10.9. Quest Diagnostics Incorporated
10.10. F. Hoffmann-La Roche Ltd
Download Sample
Choose License Type
2850
5250
4500
1800
Frequently Asked Questions
The Global Cancer Predictive Genetic Testing Market was esteemed at USD 3.88 Billion in 2022 and is projected to a value of USD 8.82 Billion by 2030, growing at a fast CAGR of 10.81% during the forecast period 2023-2030
The Global Cancer Predictive Genetic Testing Market drives Increasing Awareness and Focus on Early Cancer Detection
The Segments under the Global Cancer Predictive Genetic Testing Market by Cancer Type are Breast Cancer, Colorectal Cancer, and Ovarian Cancer
China, Japan, South Korea, Singapore, and India are the most dominating countries in the Asia Pacific region for the Global Cancer Predictive Genetic Testing Market
23&Me Inc., Abbott Laboratories, and Myriad Genetics Inc. are the three major leading players in the Global Cancer Predictive Genetic Testing Market.
